Jan Christiaan Wilschut

Jan Christiaan Wilschut's AcademicInfluence.com Rankings

Chemistry

#3589

World Rank

#4618

Historical Rank

Physical Chemistry

#498

World Rank

#549

Historical Rank

chemistry Degrees

Jan Christiaan Wilschut

Physics

#6019

World Rank

#7921

Historical Rank

Biophysics

#236

World Rank

#247

Historical Rank

physics Degrees

Download Badge

Chemistry
Physics

Jan Christiaan Wilschut's Degrees

PhD Biophysics University of Groningen
Masters Chemistry University of Groningen
Bachelors Chemistry University of Groningen

Why Is Jan Christiaan Wilschut Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jan Christiaan Wilschut's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Fluorescence method for measuring the kinetics of fusion between biological membranes. (1984) (618)
Dissecting the Cell Entry Pathway of Dengue Virus by Single-Particle Tracking in Living Cells (2008) (446)
Studies on the mechanism of membrane fusion: kinetics of calcium ion induced fusion of phosphatidylserine vesicles followed by a new assay for mixing of aqueous vesicle contents. (1980) (443)
Dengue virus life cycle: viral and host factors modulating infectivity (2010) (430)
Flavivirus Cell Entry and Membrane Fusion (2011) (256)
Characterization of the Early Events in Dengue Virus Cell Entry by Biochemical Assays and Single-Virus Tracking (2007) (248)
Studies on the mechanism of membrane fusion. Role of head-group composition in calcium- and magnesium-induced fusion of mixed phospholipid vesicles. (1981) (246)
The virosome concept for influenza vaccines. (2005) (240)
Calcium/magnesium specificity in membrane fusion: kinetics of aggregation and fusion of phosphatidylserine vesicles and the role of bilayer curvature. (1981) (238)
Immature Dengue Virus: A Veiled Pathogen? (2010) (237)
Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling (2008) (227)
Ca2+-induced fusion of phospholipid vesicles monitored by mixing of aqueous contents (1979) (220)
Membrane fusion of Semliki Forest virus involves homotrimers of the fusion protein (1992) (210)
Aggregation and fusion of phospholipid vesicles (1983) (208)
Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities (2008) (189)
Interaction of the HIV-1 fusion peptide with phospholipid vesicles: different structural requirements for fusion and leakage. (1994) (188)
Membrane fusion of Semliki Forest virus in a model system: correlation between fusion kinetics and structural changes in the envelope glycoprotein. (1993) (185)
Functional reconstitution of influenza virus envelopes. (1987) (177)
Membrane fusion of Semliki Forest virus requires sphingolipids in the target membrane. (1994) (175)
Functional importance of dengue virus maturation: infectious properties of immature virions. (2008) (158)
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease (2005) (155)
Virosome-mediated delivery of protein antigens to dendritic cells. (2002) (155)
Membrane fusion activity of the influenza virus hemagglutinin: interaction of HA2 N-terminal peptides with phospholipid vesicles. (1991) (150)
Low-pH-Dependent Fusion of Sindbis Virus with Receptor-Free Cholesterol- and Sphingolipid-Containing Liposomes (1999) (147)
Membrane fusion: lipid vesicles as a model system. (1986) (147)
Kinetics of pH-dependent fusion between influenza virus and liposomes. (1985) (146)
Fusion activity of influenza virus. A comparison between biological and artificial target membrane vesicles. (1986) (136)
Membrane fusion and the lamellar-to-inverted-hexagonal phase transition in cardiolipin vesicle systems induced by divalent cations. (1999) (132)
Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system. (2000) (132)
Physicochemical characterization of large unilamellar phospholipid vesicles prepared by reverse-phase evaporation. (1983) (131)
Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. (2008) (130)
Effects of low pH on influenza virus. Activation and inactivation of the membrane fusion capacity of the hemagglutinin. (1987) (128)
Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. (2001) (127)
Needle-free influenza vaccination. (2010) (124)
Neuroinvasive flavivirus infections (2012) (122)
MEMBRANE-FUSION - FROM LIPOSOMES TO BIOLOGICAL-MEMBRANES (1984) (118)
A small molecule fusion inhibitor of dengue virus. (2009) (118)
Virosomes for antigen and DNA delivery. (2005) (116)
Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step (2009) (111)
GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. (2012) (111)
Evaluation of viral membrane fusion assays. Comparison of the octadecylrhodamine dequenching assay with the pyrene excimer assay. (1993) (110)
Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. (2005) (105)
Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. (1997) (104)
Molecular Mechanisms Involved in Antibody‐Dependent Enhancement of Dengue Virus Infection in Humans (2013) (104)
Modulation of membrane fusion by membrane fluidity: temperature dependence of divalent cation induced fusion of phosphatidylserine vesicles. (1985) (103)
Action of phospholipases A2 on phosphatidylcholine bilayers. Effects of the phase transition, bilayer curvature and structural defects. (1978) (103)
A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes (2009) (101)
The rate of fusion of phospholipid vesicles and the role of bilayer curvature. (1982) (100)
Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles (1999) (97)
Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. (2000) (97)
Adaptation of Alphaviruses to Heparan Sulfate: Interaction of Sindbis and Semliki Forest Viruses with Liposomes Containing Lipid-Conjugated Heparin (2002) (97)
Studies on the mechanism of membrane fusion: role of phosphate in promoting calcium ion induced fusion of phospholipid vesicles. (1980) (94)
Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat‐labile enterotoxin and its B subunit (1998) (93)
Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. (1995) (93)
Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs (2008) (90)
Sphingolipid and Cholesterol Dependence of Alphavirus Membrane Fusion (2002) (89)
Membrane fusion activity of influenza virus. Effects of gangliosides and negatively charged phospholipids in target liposomes. (1989) (87)
Mass action kinetics of vesicle aggregation and fusion (1983) (86)
Induction of Heterosubtypic Cross-Protection against Influenza by a Whole Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity (2012) (85)
Musosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen (1998) (83)
Mass action kinetics of phosphatidylserine vesicle fusion as monitored by coalescence of internal vesicle volumes. (1980) (82)
Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes). (1994) (82)
Preparation, properties, and applications of reconstituted influenza virus envelopes (virosomes). (1993) (82)
Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice (2012) (81)
Modulation of membrane fusion by ionotropic and thermotropic phase transitions. (1984) (78)
Characterization of the fusogenic properties of Sendai virus: kinetics of fusion with erythrocyte membranes. (1985) (77)
Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. (2011) (76)
Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination (2008) (76)
Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. (2003) (76)
Fusion of influenza virus in an intracellular acidic compartment measured by fluorescence dequenching. (1987) (73)
Parameters affecting fusion between Sendai virus and liposomes. Role of viral proteins, liposome composition, and pH. (1986) (72)
Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7 (2002) (72)
Superior Therapeutic Efficacy of Alphavirus-Mediated Immunization against Human Papilloma Virus Type 16 Antigens in a Murine Tumour Model: Effects of the Route of Immunization (2004) (72)
Kinetics of Ca2+-induced fusion of cardiolipin-phosphatidylcholine vesicles: correlation between vesicle aggregation, bilayer destabilization, and fusion. (1985) (71)
Assembly and entry mechanisms of Semliki Forest virus. (1994) (70)
Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs (2002) (70)
Influenza vaccines: the virosome concept. (2009) (70)
Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity. (2003) (70)
Fusion of influenza virus with cardiolipin liposomes at low pH: mass action analysis of kinetics and extent. (1986) (68)
Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin (1996) (68)
A Fusion-Loop Antibody Enhances the Infectious Properties of Immature Flavivirus Particles (2011) (66)
Intracellular membrane fusion. (1989) (64)
Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. (2009) (63)
Preservation of the Immunogenicity of Dry-powder Influenza H5N1 Whole Inactivated Virus Vaccine at Elevated Storage Temperatures (2010) (62)
Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine? (2009) (62)
Antiviral activity of human lactoferrin: inhibition of alphavirus interaction with heparan sulfate. (2005) (61)
Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. (2007) (61)
Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. (2010) (59)
Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. (2011) (58)
Partial maturation: an immune-evasion strategy of dengue virus? (2011) (57)
Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. (2012) (57)
Sphingolipids activate membrane fusion of Semliki Forest virus in a stereospecific manner. (1995) (57)
Fusion assays monitoring intermixing of aqueous contents. (1993) (56)
Characterization of the functional requirements of West Nile virus membrane fusion. (2010) (56)
RETENTION OF AQUEOUS CONTENTS DURING DIVALENT CATION-INDUCED FUSION OF PHOSPHOLIPID-VESICLES (1983) (56)
Mutational analysis of the role of ADP‐ribosylation activity and GM1 ‐binding activity in the adjuvant properties of the Escherichia coli heat‐labile enterotoxin towards intranasally administered keyhole limpet hemocyanin (1998) (54)
Sphingolipid-dependent fusion of Semliki Forest virus with cholesterol-containing liposomes requires both the 3-hydroxyl group and the double bond of the sphingolipid backbone (1995) (54)
Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. (1995) (54)
Fusion of Semliki Forest virus with cholesterol-containing liposomes at low pH: a specific requirement for sphingolipids. (1995) (53)
Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. (2009) (53)
The involvement of the lipid phase transition in the plasma-induced dissolution of multilamellar phosphatidylcholine vesicles. (1979) (50)
Immature Dengue Virus Is Infectious in Human Immature Dendritic Cells via Interaction with the Receptor Molecule DC-SIGN (2014) (50)
Influenza virosomes in vaccine development. (2003) (50)
Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigen. (1995) (49)
Monitoring virus entry into living cells using DiD-labeled dengue virus particles. (2011) (49)
Role of the M2 protein in influenza virus membrane fusion: effects of amantadine and monensin on fusion kinetics. (1993) (49)
Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs (2006) (49)
Dengue seroprevalence and risk factors for past and recent viral transmission in Venezuela: a comprehensive community-based study. (2014) (48)
The role of ADP‐ribosylation and GM1‐binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat‐labile enterotoxin and Vibrio cholerae cholera toxin (1998) (48)
Role of antibodies in controlling dengue virus infection. (2009) (48)
Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice (2005) (48)
Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents (2012) (48)
Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model (2011) (47)
Role of Hemagglutinin Surface Density in the Initial Stages of Influenza Virus Fusion: Lack of Evidence for Cooperativity (2000) (47)
Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. (1998) (46)
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. (2006) (46)
A systematic review of the health economic consequences of quadrivalent influenza vaccination (2017) (46)
Calcium- and magnesium-induced fusion of mixed phosphatidylserine/phosphatidylcholine vesicles: Effect of ion binding (1981) (46)
Antibodies against the Envelope Glycoprotein Promote Infectivity of Immature Dengue Virus Serotype 2 (2012) (45)
A Single Mutation in the E2 Glycoprotein Important for Neurovirulence Influences Binding of Sindbis Virus to Neuroblastoma Cells (2002) (45)
Ca2+-induced fusion of cardiolipin/phosphatidylcholine vesicles monitored by mixing of aqueous contents. (1982) (44)
Membrane fusion activity of Semliki Forest virus in a liposomal model system: specific inhibition by Zn2+ ions. (1997) (43)
Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming. (2004) (42)
Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7 (2000) (42)
Evaluation of an Intranasal Virosomal Vaccine against Respiratory Syncytial Virus in Mice: Effect of TLR2 and NOD2 Ligands on Induction of Systemic and Mucosal Immune Responses (2013) (41)
Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit. (1996) (40)
Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine. (2014) (40)
Behavior of a photoactivatable analog of cholesterol, 6‐photocholesterol, in model membranes (2002) (39)
Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. (2013) (39)
Involvement of morbilliviruses in the pathogenesis of demyelinating disease (2007) (38)
Exchange of phosphatidylcholine between small unilamellar liposomes and human plasma high-density lipoprotein involves exclusively the phospholipid in the outer monolayer of the liposomal membrane. (1983) (38)
Reconstitution and fusogenic properties of Sendai virus envelopes. (1985) (37)
Three atypical lethal cases associated with acute Zika virus infection in Suriname (2016) (37)
Therapeutic vaccination against chronic hepatitis C virus infection. (2012) (35)
Enhancement of the Immunogenicity and Protective Efficacy of a Mucosal Influenza Subunit Vaccine by the Saponin Adjuvant GPI-0100 (2012) (35)
Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats. (2013) (35)
Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes. (2006) (35)
Ca2+-induced fusion of phosphatidylserine vesicles: mass action kinetic analysis of membrane lipid mixing and aqueous contents mixing. (1985) (35)
A synthetic peptide corresponding to the C‐terminal 25 residues of phage MS2 coded lysis protein dissipates the protonmotive force in Escherichia coli membrane vesicles by generating hydrophilic pores. (1988) (35)
Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. (2012) (35)
Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. (2007) (34)
Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. (2009) (34)
Critical Role of TLR7 Signaling in the Priming of Cross-Protective Cytotoxic T Lymphocyte Responses by a Whole Inactivated Influenza Virus Vaccine (2013) (34)
Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands (2013) (33)
First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers (2020) (33)
Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study. (2020) (33)
VIROSOMES IN VACCINE DEVELOPMENT: INDUCTION OF CYTOTOXIC T LYMPHOCYTE ACTIVITY WITH VIROSOME-ENCAPSULATED PROTEIN ANTIGENS (2002) (33)
Delivery of Foreign Substances to Cells Mediated by Fusion-Active Reconstituted Influenza Virus Envelopes (Virosomes) (1993) (32)
Semliki Forest virus produced in the absence of the 6K protein has an altered spike structure as revealed by decreased membrane fusion capacity. (2004) (31)
5HT4 agonists inhibit interferon-γ-induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes (2006) (31)
Heterosubtypic cross‐protection induced by whole inactivated influenza virus vaccine in mice: influence of the route of vaccine administration (2013) (30)
Fusion of alphaviruses with liposomes is a non‐leaky process (2002) (30)
On discounting of health gains from human papillomavirus vaccination: effects of different approaches. (2012) (29)
Targeting influenza virosomes to ovarian carcinoma cells (2001) (29)
Action of phospholipase A2 on phospholipid vesicles (1979) (29)
Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses. (2014) (28)
TARGETED LIPOSOMES FOR DELIVERY OF PROTEIN-BASED DRUGS INTO THE CYTOPLASM OF TUMOR CELLS (2002) (28)
Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF (2001) (28)
PE2 Cleavage Mutants of Sindbis Virus: Correlation between Viral Infectivity and pH-Dependent Membrane Fusion Activation of the Spike Heterodimer (2001) (28)
Agglutination and fusion of globoside GL-4 containing phospholipid vesicles mediated by lectins and calcium ions. (1985) (27)
Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. (2009) (27)
A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer (2007) (26)
Hydrolysis of phosphatidylcholine liposomes by phospholipases A2. Effects of the local anesthetic dibucaine. (1976) (26)
Fusion of erythrocyte ghosts induced by calcium phosphate. Kinetic characteristics and the role of Ca2+, phosphate and calcium-phosphate complexes. (1985) (25)
A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats (2013) (25)
Inhibition of influenza virus fusion by polyanionic proteins. (1997) (24)
A Virosomal Immunization Strategy against Cervical Cancer and Pre-Malignant Cervical Disease (2006) (24)
Ca2+-independent, protein-mediated fusion of chromaffin granule ghosts with liposomes. (1984) (24)
Ca2+-induced fusion of large unilamellar phosphatidylserine/cholesterol vesicles. (1987) (24)
Activation of murine lymphocytes by lipopolysaccharide incorporated in fusogenic, reconstituted influenza virus envelopes (virosomes). (1996) (24)
Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs (2006) (24)
Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine. (2011) (24)
Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition (2008) (24)
Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. (2011) (24)
Cost-effectiveness of vaccination against herpes zoster (2014) (23)
Further evidence for favorable cost-effectiveness of elderly influenza vaccination (2006) (23)
Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. (2009) (23)
Enantioselective synthesis of a novel trans double bond ceramide analogue via catalytic asymmetric dihydroxylation of an enyne. The role of the trans double bond of ceramide in the fusion of semliki forest virus with target membranes (1999) (22)
Innate Responses Induced by Whole Inactivated Virus or Subunit Influenza Vaccines in Cultured Dendritic Cells Correlate with Immune Responses In Vivo (2015) (22)
Fusion of reconstituted influenza virus envelopes with liposomes mediated by streptavidin/biotin interactions (1996) (22)
Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis (2009) (21)
Liposomes as target membranes in the study of virus receptor interaction and membrane fusion. (2003) (21)
The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes. (2010) (19)
Inhibition of Various Steps in the Replication Cycle of Vesicular Stomatitis Virus Contributes to Its Photoinactivation by AIPcS4 or Pc4 and Red Light (1999) (19)
Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. (2013) (19)
Low pH-induced fusion of liposomes with membrane vesicles derived from Bacillus subtilis. (1985) (19)
Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis (2017) (19)
Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: comparison to adenovirus. (1997) (18)
Role of Regulatory T-Cells in Immunization Strategies Involving a Recombinant Alphavirus Vector System (2011) (18)
Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia. (2016) (18)
Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control (2017) (18)
Ca(2+)-induced fusion of phospholipid vesicles containing free fatty acids: modulation by transmembrane pH gradients. (1992) (18)
Kinetics of calcium phosphate-induced fusion of human erythrocyte ghosts monitored by mixing of aqueous contents. (1983) (17)
Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing (2014) (17)
Liposomes as a Mucosal Adjuvant System: An Intranasal Liposomal Influenza Subunit Vaccine and the Role of IgA in Nasal Anti-Influenza Immunity (1994) (17)
Destabilization and fusion of zwitterionic large unilamellar lipid vesicles induced by a beta-type structure of the HIV-1 fusion peptide (1998) (17)
Virosomes as an Antigen Delivery System (2000) (17)
Cellular Delivery of siRNA Mediated by Fusion-Active Virosomes (2007) (17)
The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective (2015) (16)
Neutrophil-endothelial interactions in respiratory syncytial virus bronchiolitis: An understudied aspect with a potential for prediction of severity of disease. (2019) (16)
Preservation of Influenza Virosome Structure and Function During Freeze-Drying and Storage (2007) (16)
The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach. (2007) (16)
Control of Membrane Fusion by Divalent Cations, Phospholipid Head-Groups and Proteins (1985) (15)
Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies (2013) (15)
Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration. (2015) (15)
Slow fusion of liposomes composed of membrane-spanning lipids. (1997) (15)
Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines (2018) (14)
Reversible Acid-Induced Inactivation of the Membrane Fusion Protein of Semliki Forest Virus (2005) (14)
Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly (2019) (13)
Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta (2002) (13)
Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine. (2012) (13)
Deacylation of the transmembrane domains of Sindbis virus envelope glycoproteins E1 and E2 does not affect low‐pH‐induced viral membrane fusion activity (2001) (13)
Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease. (2019) (13)
Viral Fusion Mechanisms (1993) (12)
Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. (2010) (12)
Intervesicular exchange of lipids with weak acid and weak base characteristics: influence of transmembrane pH gradients. (1989) (12)
Reactivation of β‐hydroxybutyrate dehydrogenase by phosphatidylcholine/phosphatidylethanolamine mixtures: Evidence for a temperature‐induced phase separation (1976) (12)
Excess drug prescriptions during influenza and RSV seasons in the Netherlands: Potential implications for extended influenza vaccination (2008) (11)
Transient expression of a mitochondrial precursor protein. A new approach to study mitochondrial protein import in cells of higher eukaryotes. (1996) (11)
Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach (2016) (11)
Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability (2018) (11)
Membrane fusion of artificial and biological membranes. Role of local membrane dehydration (1989) (11)
The effect of partial degradation of mitochondrial phospholipids by phospholipase A on the temperature dependence of succinate-cytochrome c reductase and cytochrome c oxidase. (1974) (10)
Molecular mechanisms of membrane fusion and applications of membrane fusion techniques. (1988) (9)
Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis. (2011) (8)
Influenza vaccination in healthcare workers; comparison of side effects and preferred route of administration of intradermal versus intramuscular administration. (2017) (8)
Factors associated with the uptake of newly introduced childhood vaccinations in Ethiopia: the cases of rotavirus and pneumococcal conjugate vaccines (2019) (8)
Semliki Forest virus is an efficient and selective vector for gene delivery in infarcted rat heart. (2004) (8)
[Dengue: a growing risk to travellers to tropical and sub-tropical regions]. (2009) (7)
Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination (2013) (7)
A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer (2008) (7)
Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes (2000) (7)
The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity. (2008) (7)
Kinetics and extent of virus-cell aggregation and fusion (1993) (7)
Comparing the impact of high-dose versus standard dose influenza vaccines on hospitalization cost for cardiovascular and respiratory diseases: Economic assessment in the US Veteran population during 5 respiratory seasons using an instrumental variable method. (2020) (7)
Viral causes of severe acute respiratory infection in hospitalized children and association with outcomes: A two-year prospective surveillance study in Suriname (2021) (7)
Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza (2012) (7)
Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes (2008) (6)
Non-toxic variants of the Escherichia coli heat-labile enterotoxin as mucosal immunogens and adjuvants (1998) (6)
Nanoaggregates of micropurified lipopolysaccharide identified using dynamic light scattering, zeta potential measurement, and TLR4 signaling activity. (2012) (6)
Water transport in Biological Membranes (1989) (6)
Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines (2001) (5)
CHAPTER 2.6 – Liposomes and virosomes as immunoadjuvant and antigen-carrier systems in vaccine formulations (1998) (5)
Efficient encapsulation of plasmid DNA in anionic liposomes by a freeze/thaw extrusion procedure (1998) (5)
[Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses]. (2009) (4)
Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006. (2010) (4)
REVIEW Neuroinvasive flavivirus infections (2012) (4)
Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands (2020) (4)
Cost-effectiveness of paediatric influenza vaccination in the Netherlands (2020) (4)
Evaluation of a Liposome-Supplemented Intranasal Influenza Subunit Vaccine in a Murine Model System: Induction of Systemic and Local Mucosal Immunity (2000) (4)
Interaction of non-enveloped plant viruses and their viral coat proteins with phospholipid vesicles. (1991) (4)
Kinetics and Extent of Fusion of Influenza Virus and Sendai Virus with Liposomes (1988) (4)
Abstracts of papers and posters (2005) (3)
The Role of N-Linked Glycosylation of Sindbis Virus Glycoproteins E2 and E1 in Viral Infectivity and Membrane Fusion Activity (2002) (3)
University of Groningen Critical Role of TLR7 Signaling in the Priming of Cross-Protective Cytotoxic T Lymphocyte Responses by a Whole Inactivated Influenza Virus Vaccine Budimir, (2013) (3)
[Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance]. (2010) (3)
Critical Role of TLR 7 Signaling in the Priming of Cross-Protective Cytotoxic T Lymphocyte Responses by a Whole Inactivated Influenza Virus Vaccine (2013) (3)
The ‘Dynamic’ Marriage Between Varicella and Zoster (2015) (2)
Cardiac overexpression of human VEGF165 by recombinant Semliki Forest virus leads to adverse effects in pressure-induced heart failure (2007) (2)
Virosomes as a vaccine delivery system (2000) (2)
PIN45 COST-EFFECTIVENESS OF A COCOONING IMMUNIZATION STRATEGY AGAINST PERTUSSIS FOR THE NETHERLANDS (2009) (2)
Interaction of Influenza A/H1N1pdm Virus with Human Neuronal and Ocular Cells (2013) (2)
Age Should Women Be Vaccinated Against HPV Infection ? Recommendation Based on Cost-effectiveness Analyses (2011) (2)
PIN51 UPDATING THE COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS (2010) (2)
Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity Lost (2020) (2)
MASS-ACTION KINETICS OF PHOSPHOLIPID VESICLE FUSION AND AGGREGATION (1982) (2)
Reconstructing the Effectiveness of Policy Measures to Avoid Next-Wave COVID-19 Infections and Deaths Using a Dynamic Simulation Model: Implications for Health Technology Assessment (2022) (2)
Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands (2012) (1)
Influenza vaccination in Wegener's granulomatosis patients with quiescent disease (2007) (1)
PCN13 Analysis of the Impact of Prophylactic Vaccination Against Human Papillomavirus Infection Using a Dynamic-Modelling Approach (2012) (1)
Medical applications of liposomes (1998) (1)
Action of phospholipase A2 on membranes : A study on model membrane systems and on the lipid dependence of betha-hydroxybutyrate dehydrogenase (1978) (1)
Membrane Fusion Activity of Influenza Virus and Reconstituted Viral Envelopes (Virosomes) (1991) (1)
The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands (2020) (1)
Severity of acute Zika virus infection: A prospective emergency room surveillance study during the 2015–2016 outbreak in Suriname (2017) (1)
Genetic immunization against cervical cancer (2001) (1)
Requirement of respiratory support in acute bronchiolitis in infants is linked to endothelial and neutrophil activation (2021) (1)
VA8 HOW SHOULD HEALTH GAINS OF VACCINATION STRATEGIES BE DISCOUNTED (2009) (1)
PIN78 Cost Utility of Infant Vaccination Against Respiratory Syncytial Virus Infection in the Netherlands (2011) (1)
Fusion Activity of Influenza Virus and Reconstituted Viral Envelopes: Direct Evidence for Fusion in an Intracellular Acidic Compartment (1988) (1)
Antibody and cell-mediated responses to influenza vaccination in patients with systemic lupus erythematosus and, healthy controls (2008) (1)
LIPOSOMES, PT B (2003) (0)
Doelmatigheid van Humaan papillomavirus-vaccinatie--schattingen op basis van Nederlandse kosteneffectiviteitanalyses. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses] (2009) (0)
PIN55 Cost-Effectiveness of Hepatitis C VIRUS Screening, and Subsequent Monitoring or Treatment Among Pregnant Women in the Netherlands (2020) (0)
Interactions Of Liposomes With Plasma Proteins (2018) (0)
Transfection of murine and human dendritic cells with recombinant Semliki Forest virus (1998) (0)
Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing (2013) (0)
Fusion inactivation of H5N1 whole inactivated virus (WIV) vaccine does not compromise its superior immunogenicity (2008) (0)
Improved vaccines against respiratory viral infections for the elderly (2009) (0)
Pre-clinical testing of T cell responses to influenza vaccine/adjuvant combinations in older adults (132.5) (2009) (0)
Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study (2021) (0)
PIN68 THE COST-EFFECTIVENESS OF HEPATITIS C VIRUS SCREENING AND TREATMENT STRATEGIES AMONG RECENTLY ARRIVED MIGRANTS FOR THE NETHERLANDS (2019) (0)
Mucosal immunoadjuvant activity of liposomes (2018) (0)
Immunogenicity and safety of human papillomavirus ( HPV ) vaccination in Asian populations from six countries (2017) (0)
Pharmacoeconomics 2007; 25 (6): 497-509 (2018) (0)
RSV Vaccine Containing 3 D-PHADA ( R ) Adjuvant (2018) (0)
[Human immunodeficiency virus (HIV) infection: psychiatric aspects]. (1988) (0)
Development of a vaccine against colon carcinoma based on cytokine-transduced autologous tumor cells (1997) (0)
Induction of systemic and mucosal immunity in mice by intranasal administration of liposomal influenza and siv subunit vaccines (1993) (0)
MODULATION OF DIVALENT CATION-INDUCED MEMBRANE-FUSION BY IONOTROPIC AND THERMOTROPIC PHASE-TRANSITIONS (1983) (0)
Development of a Virosomal RSV Vaccine Containing 3D -PHAD® Ad juvant : Formu la t i on , Compos i t i on , and Long-Term Stability (2018) (0)
Vaccination and immunotherapy of viral diseases (PP-069) (2010) (0)
Action of phospholipase A2 on membranes (1978) (0)
Chapter 6 A virosomal therapeutic immunization strategy against cervical cancer and premalignant cervical disease (2019) (0)
Liposomes and virosomes as immunoadjuvants and antigencarrier systems in vaccine formulations, in: Medical applications of liposomes (1998) (0)
Recombinant Semliki Forest virus: perspectives for selective gene delivery in vascular lesions during stenting (2002) (0)
Reversible Conformational Changes of Semliki Forest Virus E1 (2004) (0)
Effectiveness of the Influenza A(H1N1)pdm09 Vaccine in Adults Recommended for Annual Influenza Vaccination: A Case-Control Study (2012) (0)
IMMUNOLOGY 2004: IMMUNODEFICIENCY, INFECTIOUS DISEASES, IMMUNOMODULATION, AND VACCINES (2004) (0)
Development of an immunotherapeutic strategy against (pre) malignant cervical cancer based on the use of fusion-active virosomes containing HPV E6/E7 recombinant protein (2001) (0)
Host defense against tumour growth (2002) (0)
Mucosal immunogenicity and adjuvanticity of the E. coli heat-labile enterotoxin: Role of the A subunit (1997) (0)
RoleofGM,binding inthemucosal immunogenicity andadjuvant activity ofthe Escherichia coli heat-labile enterotoxin anditsBsubunit (1998) (0)
FUSION OF PHOSPHOLIPID VESICLES INDUCED BY DIVALENT CATIONS, MONITORED BY MIXING OF AQUEOUS CONTENTS (1981) (0)
Genetic immunisation against cervical cancer (2000) (0)
Interactions of Peptides with Phospholipid Vesicles: Fusion, Leakage and Flip-Flop (1995) (0)
Membrane Interactions and Fusion (2017) (0)
Portioned liquid detergent or cleaning agent (2002) (0)
Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: the case of switching to High-Dose influenza vaccine for Dutch older adults. (2022) (0)
The role of calcium and acidic phospho lipids in membrane fusion a contact induced local phase transition as a key event in membrane fusion phenomena (1980) (0)
Membrane Fusion in Lipid Vesicle Systems (2019) (0)
GENE THERAPY at the Groningen Genomics Centre (2002) (0)
Role of fusion activity in cross-presentation of influenza nucleoprotein-derived antigens (2009) (0)
University of Groningen Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling Geeraedts, (2008) (0)
SFV transfection as a means for in vivo loading of heat shock proteins with antigenic peptides (1997) (0)
PIN16 COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS (2008) (0)
OF LIPOSOMES : ROLE OF ALVEOLAR MACROPHAGES (2001) (0)
United States Patent 19 (2017) (0)
RETENTION OF AQUEOUS CONTENTS DURING CA-2+-INDUCED FUSION OF PHOSPHOLIPID-VESICLES (1983) (0)
Kinetics and extent of fusion of viruses with liposomes (1988) (0)
Reviewing cost-effectiveness of HPV- vaccination on top of screening in the specific Dutch context (2017) (0)
SYSTEMIC AND LOCAL IgG AND IgA ANTIBODY RESPONSES IN MICE INDUCED BY INTRANASAL IMMUNIZATION WITH LIPOSOME-SUPPLEMENTED INFLUENZA VIRUS SUBUNIT ANTIGEN : COMPARISON WITH ANTIBODY RESPONSES AFTER CONVENTIONAL IMMUNIZATION AND INFLUENZA INFECTION (2018) (0)
CELLULAR DELIVERY BY FUSION-ACTIVE VIROSOMES (1995) (0)
University of Groningen Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination Gefenaite, (2013) (0)
Cost-effectiveness analysis of a FOBT-based colorectal screening programme (2010) (0)
PCN65 COST-EFFECTIVENESS ANALYSIS OF A FOBT-BASED COLORECTAL CANCER SCREENING PROGRAMME (2010) (0)
Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability (2018) (0)
[Rotavirus vaccination for all Dutch infants]. (2022) (0)
Vaccine with an adjuvant consisting of LTB. (1998) (0)
[Continue to use the bivalent HPV vaccine; bivalent vaccine more effective than expected]. (2020) (0)
Cost-Effectiveness of Additional Human Papillomavirus Vaccination Programmes, in The Netherlands (2017) (0)
Development of a therapeutic vaccine against chronic Hepatitis C virus infection (2012) (0)
PREPARATION OF INFLUENZA VIROSOMES BY POST-INSERTION OF INFLUENZA VIRUS SPIKE PROTEINS INTO PREFORMED LIPOSOMES (2001) (0)
Development of stable influenza vaccine powder formulations for non-parenteral dosage forms: challenges and possibilities (2007) (0)
FUSION OF VIRUSES WITH ARTIFICIAL AND BIOLOGICAL TARGET MEMBRANES - APPLICATION OF FLUORESCENT TECHNIQUES (1985) (0)
EFIS 2000: 14TH EUROPEAN IMMUNOLOGY MEETING (2000) (0)
University of Groningen Evaluation of an Intranasal Virosomal Vaccine against Respiratory Syncytial Virus in Mice (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jan Christiaan Wilschut?

Jan Christiaan Wilschut is affiliated with the following schools:

Jan Christiaan Wilschut's Academic­Influence.com Rankings

Jan Christiaan Wilschut's Degrees

Why Is Jan Christiaan Wilschut Influential?

Jan Christiaan Wilschut's Published Works

Published Works

What Schools Are Affiliated With Jan Christiaan Wilschut?

Jan Christiaan Wilschut's AcademicInfluence.com Rankings